Form 4: ResMed Director Jan De Witte Sells Shares Under 10b5-1 Plan

ResMed director Jan De Witte sold 796 shares of common stock at $248.81 per share on November 12, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Jan De Witte, a director at ResMed Inc., sold 796 shares of the company's common stock on November 12, 2024.
• The sale was executed at a price of $248.81 per share.
• This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on February 2, 2024.
• Following the transaction, Mr. De Witte directly owns 6,723 shares of ResMed common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to a pre-planned stock sale by a director. It does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine filing related to insider trading activity. It is common for executives and directors to use 10b5-1 plans to manage their stock sales and avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among corporate insiders at publicly traded companies, including those in the medical device industry like ResMed.
• Similar filings are regularly made by directors and officers at companies like Philips and Medtronic, indicating a standard approach to managing personal stock holdings.

Stakeholder Impact

• The sale of shares by a director may have a minor impact on shareholder sentiment, but it is unlikely to significantly affect the stock price given the pre-planned nature of the transaction.

Key Dates

Keywords

ResMed, RMD, insider trading, Form 4, stock sale, 10b5-1 plan, Jan De Witte, director